Pharmalot By Ed Silverman Is it in the public’s interest to have two similar cholesterol drugs on the market?
Health By Damian Garde Raising ‘good’ cholesterol doesn’t protect against heart disease after all, study finds
Biotech By Damian Garde These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating
The Watchdogs By Ivan Oransky and Adam Marcus Why a drug that lowers cholesterol doesn’t save lives
Pharmalot By Ed Silverman Aegerion to pay $40M and plead guilty to illegally marketing cholesterol drug
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Cigna to get discounts if cholesterol meds don’t work
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Little company makes big bet on discarded Roche drug
Pharmalot By Ed Silverman Docs won’t prescribe pricey new cholesterol meds unless they lower heart risks
Health By Associated Press Cholesterol-lowering statins cut heart disease risk in people with slightly high blood pressure
Pharmalot By Ed Silverman Why one analyst thinks a Sanofi and Regeneron cholesterol drug will be yanked
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: setback for Merck, Valeant to offer discounts at Walgreens
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: US drug prices are highest, UnitedHealth favors Regeneron
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: CVS covers new cholesterol drug, FDA Duchenne hearing